Moleculin Biotech, Inc. 8-K

What Happened
Moleculin Biotech, Inc. announced on February 17, 2026 (via an 8-K Item 7.01 Regulation FD disclosure) that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.” The company said a patent based on this application is expected to be issued in the coming months. A press release describing the notice was attached to the filing as Exhibit 99.1.

Key Details

• JPO issued a notice of allowance for Patent Application No. 2021-577862.
• Patent title: “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.”
• Filing disclosed via Form 8-K dated February 17, 2026 under Item 7.01 (Regulation FD); press release attached as Exhibit 99.1.
• Company expects an issued patent in Japan in the coming months.

Why It Matters
A notice of allowance means the JPO has indicated it will grant a patent for the described reconstitution method once formal steps are completed. If issued, the patent would provide intellectual property protection in Japan for that specific method, which is a concrete legal asset the company can cite publicly. This disclosure is material information for investors because it affects Moleculin’s IP position in a key market and may be relevant to future development, licensing or regulatory activities related to liposomal annamycin.